Research:To Focus on New, Non-invasive Early Detection LC

[Barb73]

http://www.medicalnewstoday.com/articles/103597.php

ARTICLE:

. . . . . . . . .

Researchers and executives from Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, will present a paper entitled "New Non-Invasive Technology for the Early Detection of Cancer at the Cellular Level" at the 83rd Annual Multidisciplinary Meeting of the American Association for the Advancement of Science (AAAS) Southwestern and Rocky Mountain (SWARM) Division, Thursday, April 10, in Albuquerque.

The paper will focus on Biomoda's non-invasive and cost-efficient screening technology for early detection of lung cancer. The technology, which was developed at Los Alamos National Laboratory, is based on a patented porphyrin molecule that preferentially binds to cancerous or aberrant cells extracted from the body as sputum, blood or urine. Cancerous or aberrant cells that bind porphyrin glow red under ultraviolet light; non-cancerous cells do not fluoresce.

Current diagnostic methods for lung cancer -- the leading cause of cancer-related deaths in the United States -- often detect the disease only at more advanced stages.

"This conference is an excellent venue for Biomoda to foster communication and share our research among other scientists and engineers," said John Cousins, Biomoda President. "We are excited about the opportunity to increase public understanding of our latest advances in in-vitro diagnostics for non-invasive testing for cancer at the cellular level."

Biomoda is seeking international partners interested in collaborating in the development and use of its non-invasive early-stage cancer detection technology.

Biomoda and the New Mexico Institute of Mining and Technology (New Mexico Tech) recently announced their partnership with the New Mexico Department of Veterans Services (DVS) to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. Biomoda will conduct the first year of the clinical program, while New Mexico Tech and DVS will oversee the study and provide treatment to those veterans who test positive for lung cancer.

The New Mexico state legislature recently allocated an additional $1.3 million in funding through the Interim Tobacco Settlement Committee to the clinical screening program.

Biomoda presenters at the SWARM conference include: Cousins; Leo S. Gomez, Ph.D., Director of Research; Constance J.

Dorian, Director of Technical Operations; and Stephen M. Gomez, Ph.D., Senior Research Specialist.

. . . . . . . . .

(Medcial News Today, Lung Cancer, April 11, 2008)

Disclaimer:

The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind.